Evidence map›Paper›PMID 36670331›Full record

ArticleCardiology and therapy2023

The Use of Midodrine as an Adjunctive Therapy to Liberate Patients from Intravenous Vasopressors: A Systematic Review and Meta-analysis of Randomized Controlled Studies.

Mohamed Hamed, Sheref A Elseidy, Ahmed Elkheshen, Jamal Maher, Adel Elmoghrabi, Ahmed Zaghloul, Andrew Panakos, Sidakpal Panaich, Marwan Saad, Ayman Elbadawi

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06930235 (Effectiveness of Midodrine as an Adjuvant to Norepinephrine in Weaning Critically Ill Patients From Vasopressors), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06930235 nacompletednot on this mapstarted 2025, after this paper: background citation

Effectiveness of Midodrine as an Adjuvant to Norepinephrine in Weaning Critically Ill Patients From Vasopressors

TypeinterventionalSponsorSohag UniversityRan2025 to 2025Enrolled112ConditionsShockArmsWeaning critically ill patients from norepinephrine using midodrine as an adjuvant to norepinephrine, Weaning critically ill patients from norepinephrine without use of midodrine as an adjuvant
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Mohamed HamedDepartment of Internal Medicine, Florida Atlantic University, Boca Raton, FL, USA.
Sheref A ElseidyDepartment of Internal Medicine, Rochester General Hospital, Rochester, NY, USA.
Ahmed ElkheshenDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Jamal MaherSection of Cardiology, Baylor College of Medicine, Houston, TX, USA.
Adel ElmoghrabiDivision of Cardiology, Wayne State University/Detroit Medical Center, Detroit, MI, USA.
Ahmed ZaghloulDivision of Cardiology, University of Iowa Health Care, Iowa, IA, USA.
Andrew PanakosDivision of Cardiology, Florida Atlantic University, Boca Raton, FL, USA.
Sidakpal PanaichDivision of Cardiology, University of Iowa Health Care, Iowa, IA, USA.
Marwan SaadLifespan Cardiovascular Institute, Providence, RI, USA.
Ayman ElbadawiDivision of Cardiology, University of Texas Southwestern Medical Center, Harry Hines Blvd, Dallas, TX, 75390-9047, USA. aymangalal24@hotmail.com.ORCID http://orcid.org/0000-0002-4248-781X
Florida Atlantic University · USUniversity of Iowa Health Care · USBaylor College of Medicine · USProvidence College · USRochester General Hospital · USSouthwestern Medical Center · USTexas Tech University · USWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies evaluating the role of midodrine as an adjunctive therapy to liberate patients with shock from intravenous (IV) vasopressors have yielded mixed results. The aim of our study was to evaluate the efficacy and safety of midodrine as an adjunctive therapy to liberate patients with shock from IV vasopressors.

methodsElectronic searches of the MEDLINE, EMBASE, and Cochrane databases through April 2022 for randomized controlled trials (RCTs) that evaluated the use of midodrine versus control in patients with shock and a low dose of IV vasopressors. The primary outcome was total IV vasopressor time, while the secondary outcomes included time-to-IV vasopressor discontinuation, IV vasopressor restart, intensive care unit (ICU) length of stay (LOS), hospital LOS, and incidence of bradycardia.

resultsThe final analysis included four RCTs with a total of 314 patients: 158 in the midodrine group and 156 in the control group, with a weighted mean age of 64 years (54.2% men). There was no significant difference in the total IV vasopressor time between the midodrine and control groups (standardized mean difference [SMD] - 0.53; 95% confidence interval [CI] - 1.38 to 0.32, p = 0.22; I

conclusionsAmong patients with vasopressor-dependent shock, midodrine was not associated with early liberation of vasopressor support or shorter ICU or hospital length of stay. Adding midodrine increased the risk of bradycardia. Further large RCTs are needed to better evaluate the efficacy and safety of midodrine in liberating patients from IV vasopressors.

Indexed as

Critical careICUIntensive care unitMidodrineShockVasopressors

Identifiers

PMID36670331
PMCPMC9986154
OpenAlexW4317606025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.